Tianjin Medical University Cancer Institute And Hospital

This phase 3 study tests whether the immunotherapy drug toripalimab, given after initial chemo-immunotherapy and radiation, can delay cancer growth in people with advanced esophageal cancer that hasn't spread further. About 340 adults whose cancer responded or remained stable aft…

This study tests a new three-drug combination for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The drugs include an antibody-drug conjugate (becotatug vedotin) that targets cancer cells, an immunotherapy (tislelizumab), and stan…

This early-phase study tests a new cell therapy called CHT101 in 30 adults whose malignant brain tumors have come back or worsened despite standard treatment. The therapy uses specially engineered cells to attack tumors that show a specific marker (CD70). The main goal is to chec…

This early-phase trial tests whether giving three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The study will enroll 22 adults aged 18-75 with stage IIA-IIIB disease who have …

This study tests a new treatment for people with esophageal cancer that didn't shrink after standard therapy. Participants will get low-dose radiation, chemotherapy, and an immunotherapy drug called toripalimab before surgery. The goal is to see if adding radiation helps more tum…

This study tests a new approach for early-stage triple-negative breast cancer. Patients receive an immunotherapy drug (QL1706) plus chemotherapy. After four cycles, those whose tumors disappear on scans can skip further harsh chemo and go straight to surgery, reducing long-term h…

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. It combines the experimental drug bemotuzumab with standard chemotherapy and anlotinib, followed by chest radiation. The goal is to see if this approach can …

This study tests whether adding Retlirafusp alfa to standard chemotherapy before and after surgery can improve outcomes for people with gastroesophageal junction cancer. About 30 adults with HER2-negative, CPS>5 tumors will receive 3 cycles of the drug combo, then surgery, then p…

This study tests a combination of two drugs (utidelone and bevacizumab) with or without a third (etoposide) in 56 people with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Participants must have cer…

This study tests a new combination of drugs for people with advanced clear cell kidney cancer that has stopped responding to initial therapy. The treatment combines two immune-boosting antibodies (iparomlimab and tuvonralimab) with a targeted therapy (lenvatinib or axitinib). The…

This study tests a combination of chemotherapy (bendamustine) and targeted therapy (orelabrutinib plus an anti-CD20 antibody) as a first treatment for mantle cell lymphoma. It includes 45 adults aged 60 or older who cannot or choose not to have a stem cell transplant. The goal is…

This study tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare and aggressive type of cancer called large-cell neuroendocrine carcinoma, which can start in the lung or elsewhere in the body. The goal is to …

This study tests a combination of two drugs, Sac-TMT and Tagitanlimab, in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer that has been treated before. The goal is to see if the combination shrinks tumors or slows cancer g…

This study tests a new combination of drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. The treatment includes chemotherapy delivered directly to the liver, an oral targeted therapy, and an immunotherapy…

This study will follow 500 adults with HER2-positive advanced breast cancer who are starting treatment with pyrotinib. Researchers want to see how well the drug controls the cancer and what side effects occur. The goal is to manage the disease, not cure it.

This study is for people with HER2-negative breast cancer whose tumors did not shrink after the first round of chemotherapy. It tests whether adding an immunotherapy drug called toripalimab, sometimes with targeted radiation, can improve outcomes before and after surgery. About 1…

This study compares two doses of furmonertinib (80mg vs 160mg) combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated NSCLC) that has spread to the brain. About 60 participants who have not had prior treatment will be enrolled. The goal is to see …

This study tests different drug combinations for people with extensive-stage small cell lung cancer who haven't had treatment yet. Depending on specific markers in their tumor, participants receive one of three targeted therapies added to standard chemo-immunotherapy. The goal is…

This study tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can shrink tumors more effectively before surgery in people with stage II-III non-small cell lung cancer. Participants will receive the drug combination for four cycles, then undergo s…

This study tests whether combining the immunotherapy drug camrelizumab with chemotherapy and radiation before surgery can eliminate all signs of cancer in women with early-stage triple-negative breast cancer. About 43 women will receive the treatment for 12 weeks, then have surge…

This study tests a mix of chemotherapy drugs (liposomal irinotecan, vincristine, temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have come back or not responded to treatment. The goal is to see if the combination can shrink tu…

This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with precise radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the treatment. The goal is to see if the combinat…

This study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can lower the chance of liver cancer coming back in people with early-stage disease. About 60 adults with stage IA liver cancer and a narrow surgical margin will be randomly assigned to receive…

This study looks at 120 breast cancer patients receiving T-DXd therapy. Half get a standard anti-nausea drug combo, and the other half get a new combo with megestrol acetate. The goal is to see which works better at preventing nausea and vomiting, helping patients stay on treatme…

This study tests a drug called romiplostim N01 in 68 breast cancer patients whose platelet counts dropped too low after chemotherapy. The goal is to see if weekly injections can safely bring platelet levels back up within two weeks, allowing patients to continue their cancer trea…

This study tests a new painkiller called Anrikefon for people recovering from stomach cancer surgery. It aims to reduce the need for strong opioids and lower side effects like nausea. About 114 adults having laparoscopic gastrectomy will receive either Anrikefon or a placebo to s…

This study looks at 300 lung cancer patients whose tumors did not fully disappear after immunotherapy and surgery. Researchers will use advanced gene testing to find hidden genetic changes that may explain why the treatment didn't work as well. The goal is to better understand th…

This study looks at 860 Chinese patients with advanced kidney cancer to compare two treatment sequences: starting with one type of drug (TKI) then switching to a combination (TKI/IO), or starting with the combination then switching to the single drug. The goal is to see which ord…